The time is nigh for the DEA to cooperate in ensuring that medical marijuana research can move forward. According to MAPS and the lawsuit, the DEA has failed to process more than thirty outstanding applications to develop cannabis for research purposes for more than four years despite administrative guidance. The results of the November election approving cannabis legalization measures across the board in the U.S., coupled with the CND’s vote to remove medicinal cannabis from Schedule IV, indicates that the time is nigh for the DEA to cooperate in ensuring that medical marijuana research can move forward. The press release outlines the nature of the lawsuit as follows: “Nearly 20 years after Dr. The announcement of this lawsuit comes on the heels of the United Nations Commission for Narcotic Drugs (CND) voting to accept the World Health Organization’s (WHO) recommendation to remove cannabis and cannabis resin for medicinal purposes from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
The time is nigh for the DEA to cooperate in ensuring that medical marijuana research can move forward. Finally.
On December 3, 2020, MAPS (the Multidisciplinary Association for Psychedelic Studies) issued a press release regarding a lawsuit filed against the DEA and the Attorney General to “compel issuance of licenses to manufacture marijuana for clinical trials and potential FDA approval.” We have written about MAPS and its 35 years of advocacy and engagement with DEA before,...
Read the full article @ Fresh Toast